The dominant risk is timing: IonQ must convert technical milestones and acquisitions into repeatable, contractable products by 2028–2029. If the market stays “science-project flavored” through 2031, revenue remains lumpy, attach rates for security/timing stay unclear, and valuation can mean-revert. Secondary risks are architecture convergence (incumbents), sovereign market fragmentation, and
dilution if M&A remains equity-funded.